Rectal Suppository Therapy For Gastrointestinal Disease: Improving Patient Compliance Through Innovative Technology | 3292
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
At various times of treatment, IBD patients are prescribed suppositories and rectal medication is the
acknowledged first line treatment for mild to moderate active ulcerative colitis and other gastrointestinal
disease and ailments. Yet, patient compliance with prescribed rectal medication is abysmal, roughly 30%, leading
to advancement of disease and increased healthcare costs. A disposable suppository applicator with patented
technology transforms the value proposition for patients when deciding to adhere to their doctors prescribed
drug therapy. Patients identify quality of life issues as a leading factor in noncompliance with suppository
treatment. Lying on the left side for 30 to 45 minutes to administer the medication and the need for protective
undergarments due to leakage are barriers to compliance. The new technology allows gas flow during the
administration of the medication and withdrawal of the apparatus reducing the time for administration from
45 minutes to less than 5 seconds and allows immediate resumption of daily activities, without the need for
protective undergarments. The applicator increases patient compliance and offers a new conversation with
patients for physicians prescribing appropriate suppository medication.
Invented by a patient with firsthand knowledge of the encumbrances of suppository medication, the
device is the first and only rectal suppository applicator cleared for marketing and distribution by the FDA.
The patented, inexpensive, disposable device fits within the changing healthcare paradigm with a cost effective
medical technology that incentivizes a behavioral change on the part of chronically ill patients to become more
compliant with their prescribed rectal medication therapy.
Jennifer Davagian-Ensign is the Founder and CEO of Christcot Medical Company. As a Crohn?s patient she knows the daily
struggles of IBD patients and compliance decisions affecting healthcare outcomes. Ms. Davagian-Ensign has given several talks
including patient responsibility in compliance and the importance of new medical device technologies that motivate behavioral
changes on the part of the patient. As a thought leader in the area of rectal medication treatment for gastrointestinal disease, Ms.
Davagian-Ensign led the initiative to have Ulcerative Proctitis categorized as a Rare Genetic Orphan Disease by the NIH and wrote
the abstract included in the NIH database.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals